12/19/2008

Oncothyreon sold manufacturing rights to Stimuvax, its investigational lung cancer vaccine, to Merck KGaA for $13 million. The deal is part of a restructuring that seeks "to create a sustainable team intensely focused on our clinical-development activities," Oncothyreon CEO Robert Kirkman said.

Full Story:
The Seattle Times

Related Summaries